Sage Journals: Discover world-class research

Abstract

Genetic polymorphism of IFNAR-1 plays a large role in determining the clearance or chronicity after hepatitis B virus (HBV) exposure. However, it is not clear whether type I interferon receptor-1 (IFNAR-1) variations continuously exert their effects to influence the final outcomes following HBV chronicity, including acute-on-chronic hepatitis B liver failure (ACLF-HBV), chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC). Here we report that these four potential outcomes of chronic HBV infection are strongly associated with IFNAR-1 polymorphisms through a hospital-based case-control study of 663 cases. ACLF-HBV and HCC were each compared with CHB+LC. In comparison with the G/G genotype, the C/G and C/C genotypes at both single-nucleotide polymorphism (SNP) sites (rs1012335 and rs2257167) showed significant susceptibility to ACLF-HBV (the highest odds ratio [OR] reached 2.374; 95% CI = 1.488, 3.788; p < 0.001 for the C/G genotype at rs2257167), as well as HCC (OR = 2.475; 95% CI = 1.435, 4.426; p < 0.001 for the C/C genotype at rs1012335). The C allele at both loci was a susceptibility allele for ACLF-HBV and HCC, with the highest ORs reaching 1.653 (95% CI = 1.233, 2.216; p < 0.01 at rs1012335) in the ACLF-HBV group, and 1.659 (95% CI = 1.274, 2.159; p < 0.01 at rs1012335) in the HCC group. A strongly linked disequilibrium was also found within these two alleles (p < 0.001). Our research indicates that genetic polymorphisms of IFNAR-1 not only contribute to the determination of clearance or chronicity in the early stages of HBV exposure, but they also persistently influence pathogenesis over the long-term process of chronic HBV infection.

Get full access to this article

View all access options for this article.

References

Lavanchy

. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat, 2004; 11:97–107.

Szmaragd

, Nichols

, Balloux

. A novel approach to characterise pathogen candidate genetic polymorphisms involved in clinical outcome. Infect Genet Evol, 2006; 6:38–45.

Casanova

, Abel

. Human genetics of infectious diseases: a unified theory. EMBO J, 2007; 26:915–922.

Clementi

, Di Gianantonio

. Genetic susceptibility to infectious diseases. Reprod Toxicol, 2006; 21:345–349.

Shi

, Fu

, Shi

et al. Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection. Clin Immunol, 2009; 132:43–54.

Pham

, Mercer

, Michalak

. Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles. J Viral Hepat, 2009; 16:547–556.

Gujar

, Michalak

. Primary occult hepadnavirus infection induces virus-specific T-cell and aberrant cytokine responses in the absence of antiviral antibody reactivity in the woodchuck model of hepatitis B virus infection. J Virol, 2009; 83:3861–3876.

Le Bon

, Tough

. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol, 2002; 14:432–436.

Perry

, Chen

, Zheng

et al. The host type I interferon response to viral and bacterial infections. Cell Res, 2005; 15:407–422.

10.

Platanias

. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol, 2005; 5:375–386.

11.

de Weerd

, Samarajiwa

, Hertzog

. Type I interferon receptors: biochemistry and biological functions. J Biol Chem, 2007; 282:20053–20057.

12.

Uze

, Lutfalla

, Eid

et al. Murine tumor cells expressing the gene for the human interferon alpha beta receptor elicit antibodies in syngeneic mice to the active form of the receptor. Eur J Immunol, 1991; 21:447–451.

13.

Benoit

, Maguire

, Plavec

et al. A monoclonal antibody to recombinant human IFN-alpha receptor inhibits biologic activity of several species of human IFN-alpha, IFN-beta, and IFN-omega. Detection of heterogeneity of the cellular type I IFN receptor. J Immunol, 1993; 150:707–716.

14.

Diop

, Hirtzig

, Do

et al. Exhaustive genotyping of the interferon alpha receptor 1 (IFNAR1) gene and association of an IFNAR1 protein variant with AIDS progression or susceptibility to HIV-1 infection in a French AIDS cohort. Biomed Pharmacother, 2006; 60:569–577.

15.

Welzel

, Morgan

, Bonkovsky

et al. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology, 2009; 49:1847–1858.

16.

Fortunato

, Calcagno

, Bresciamorra

et al. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res, 2008; 28:141–152.

17.

Song Le

, Xuan

, Toan

et al. Association of two variants of the interferon-alpha receptor-1 gene with the presentation of hepatitis B virus infection. Eur Cytokine Netw, 2008; 19:204–210.

18.

Zhou

, Lu

, Yuen

et al. Polymorphisms of type I interferon receptor 1 promoter and their effects on chronic hepatitis B virus infection. J Hepatol, 2007; 46:198–205.

19.

Leyva

, Fernandez

, Fedetz

et al. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol, 2005; 163:165–171.

20.

Sriram

, Barcellos

, Villoslada

et al. Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun, 2003; 4:147–152.

21.

Tangwattanachuleeporn

, Sodsai

, Avihingsanon

et al. Association of interferon-gamma gene polymorphism (+874A) with arthritis manifestation in SLE. Clin Rheumatol, 2007; 26:1921–1924.

22.

Zhou

, Smith

, Lu

et al. A non-synonymous single nucleotide polymorphism in IFNAR1 affects susceptibility to chronic hepatitis B virus infection. J Viral Hepat, 2009; 16:45–52.

23.

Zhang

, Deriaud

, Jiao

et al. Type I interferons protect neonates from acute inflammation through interleukin 10-producing B cells. J Exp Med, 2007; 204:1107–1118.

24.

Inglefield

, Dumitru

, Alkan

et al. TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. J Interferon Cytokine Res, 2008; 28:253–263.

25.

Currie

, van der Most

, Broomfield

et al. Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J Immunol, 2008; 180:1535–1544.

26.

Aucan

, Walley

, Hennig

et al. Interferon-alpha receptor-1 (IFNAR1) variants are associated with protection against cerebral malaria in the Gambia. Genes Immun, 2003; 4:275–282.

27.

, Fu

, Jin

et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol, 2006; 177:739–747.

28.

Zeng

, Guan

, An

et al. A population-based study to investigate host genetic factors associated with hepatitis B infection and pathogenesis in the Chinese population. BMC Infect Dis, 2008; 8:1.

29.

Excoffier

, Laval

, Balding

. Gametic phase estimation over large genomic regions using an adaptive window approach. Hum Genomics, 2003; 1:7–19.

30.

Slatkin

, Excoffier

. Testing for linkage disequilibrium in genotypic data using the expectation-maximization algorithm. Heredity, 1996; 76,Pt 4:377–383.

31.

, Tan

, Hu

et al. Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature, 2007; 450:299–303.

32.

Storr

, Emmerdinger

, Diegelmann

et al. The role of fatty acid hydrolase gene variants in inflammatory bowel disease. Aliment Pharmacol Ther, 2009; 29:542–551.

33.

Amre

, Mack

, Morgan

et al. Interleukin 10 (IL-10) gene variants and susceptibility for paediatric onset Crohn's disease. Aliment Pharmacol Ther, 2009; 29:1025–1031.

34.

Suneetha

, Sarin

, Goyal

et al. Association between vitamin D receptor, CCR5, TNF-alpha and TNF-beta gene polymorphisms and HBV infection and severity of liver disease. J Hepatol, 2006; 44:856–863.

35.

Deng

, Zhou

, Zhai

et al. Association of estrogen receptor alpha polymorphisms with susceptibility to chronic hepatitis B virus infection. Hepatology, 2004; 40:318–326.

36.

, Pai

, Yang

et al. Role of N-acetyltransferase polymorphisms in hepatitis B related hepatocellular carcinoma: impact of smoking on risk. Gut, 2000; 47:703–709.

37.

Thio

, Mosbruger

, Astemborski

et al. Mannose binding lectin genotypes influence recovery from hepatitis B virus infection. J Virol, 2005; 79:9192–9196.

38.

Thio

, Astemborski

, Bashirova

et al. Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence. J Virol, 2007; 81:441–445.

39.

Ben-Ari

, Mor

, Papo

et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol, 2003; 98:144–150.

40.

Miyazoe

, Hamasaki

, Nakata

et al. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol, 2002; 97:2086–2092.

41.

Migita

, Maeda

, Abiru

et al. Polymorphisms of interleukin-1beta in Japanese patients with hepatitis B virus infection. J Hepatol, 2007; 46:381–386.

42.

, Shi

, Budhu

et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med, 2009; 361:1437–1447.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

Persistent Effect of IFNAR-1 Genetic Polymorphism on the Long-Term Pathogenesis of Chronic HBV Infection

Abstract

Get full access to this article

References

Supplementary Material